Covestor’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Covestor’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2	Closed	–	–	2885
2023 Q2	$0	Sell	2 -1	-33%	-$95	﹤0.01%	2815
2023 Q1	$0	Hold	3	–	–	﹤0.01%	2750
2022 Q4	$0	Hold	3	–	–	﹤0.01%	2771
2022 Q3	$0	Buy	+3	New	+$83	﹤0.01%	2795

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Covestor's RETA Position: Q3 2023 in Review

Covestor sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2 shares.

Covestor first reported a position in RETA in Q3 2022 and held it in 4 quarters. The position peaked at $0 in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Covestor reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Covestor sold 2 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023.
Covestor first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2022 and held it in 4 quarters.
Covestor's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $0 in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Covestor's 13F filing for Q3 2023, filed 13 Nov 2023.